Immune-mediated inflammatory diseases, including rheumatoid arthritis, axial spondyloarthritis, psoriasis, hidradenitis suppurativa, and inflammatory bowel disease, affect up to 10% of the Western population. Due to their overlapping pathogeneses, these chronic inflammatory diseases are now treated according to their pathological mechanism. These mechanisms involve the increased production of the cytokine tumour necrosis factor (TNF)-α, leading to excessive inflammation and consequently to organ damage.
Latest articlesAll articles
Anti-TNF Treatment in Crohn’s Disease Complicated by Intra-abdominal Abscess
Excess production of TNF-α leads to chronic inflammation and tissue damage in immune-mediated inflammatory diseases (IMID) such as Crohn’s Disease (CD), rheumatoid arthritis, and psoriasis. The introduction of anti-TNF agents revolutionised therapy for patients with IMIDs, and two anti-TNFs are currently approved for use in CD in Europe: infliximab and adalimumab.
Gastric Pouch Gastrointestinal Stromal Tumour Post-Roux-en-Y Gastric Bypass: A First Reported Case
Gastric gastrointestinal stromal tumour is an extremely rare condition to occur after bariatric surgery. To the authors’ knowledge, only two cases of gastric gastrointestinal stromal tumours after Roux-en-Y gastric bypass have been reported in the medical literature, both occurring in the excluded gastric remnant. Herein, the authors report the third case of gastric gastrointestinal stromal tumour post-Roux-en-Y gastric bypass, and the first case to occur in the gastric pouch, which was managed surgically by laparoscopic resection. From here, combining the observations of clinicians treating and following up patients post-bariatric surgery in an international database will be beneficial to patients, and aid in development of surveillance guidelines.
The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to Acceptance
The over-production of TNF-α can lead to chronic inflammation and organ damage in immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis (RA), axial spondyloarthritis, psoriasis, and inflammatory bowel disease (IBD). Anti-TNF therapy is generally considered to be an effective, well-tolerated treatment option for the management of chronic inflammation in these conditions.